MultiHance®
MultiHance® (gadobenatode dimeglumina/Gd-BOPTA) é um meio de contraste de alta relaxatividade com:
- maior relaxatividade longitudinal (r1) versus outros quelatos de gadolínio.1-3
- maior relaxatividade em todas as concentrações de campo clinicamente relevantes versus outros meios de contraste extracelulares à base de gadolínio em todos os campos magnéticos até 3T.2
Em razão da sua alta relaxatividade, o MultiHance® produz melhor realce do contraste e visualização superior da lesão em comparação ao gadopentetatode dimeglumina, gadobutrole gadodiamidana Ressonância Magnética (RM) do Sistema Nervoso Central (SNC).4-8
O MultiHance® proporcionou desempenho diagnóstico superior vs. gadopentetatode dimeglumina(Gd-DTPA) na RM de Mama e na Angio-RM.9-12
Devido sua dupla excreção (renal e por vias biliares), o MultiHance® também possui capacidade de ser um meio de contraste hepatobiliar, fornecendo informações adicionais na fase de retardo, melhorando a detecção de metástase e permitindo a caracterização precisa de lesões focais hepáticas. 13-22
Indicado para RM do cérebro, fígado e mama, e Angio-RM.28
- Mais de 17,5 milhões de doses administradas em todo o mundo desde o seu lançamento em 1998.27
- Perfil de segurança estabelecido. 23-26
Referências bibliográficas:
1. High-relaxivity contrast-enhancedmagneticre sonanceneuroimaging: a review.
Giesel, F.L. e t al. Eur. Radiol. 2010; 20(10):2461-74.
2. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.
Shen Y, Goerner FL, Snyder C, et al. Invest Radiol. 2015;50:330–338. 3.
3. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.
Pintaske, J. et al. Invest. Radiol. 2006; 41(3):213-21.
4. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.
Maravilla, K.R. et al. Radiology. 2006; 240(2):389-400.
5. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla.
Rumboldt, Z. et al. J. Ma gn. Reson. Imaging. 2009; 29(4):760-7.
6. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
Rowley, H.A. et al. AJNR Am. J. Neuroradiol. 2008; 29(9):1684-91.
7. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours.
Colosimo, C. et al. Neuroradiology. 2004; 46(8):655-65.
8. Seidl, Z. et al. Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT study).
AJNR Am. J. Neuroradiol. 2012; 33(6):1050-8.
9. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
Pediconi, F. et al. AJR Am. J. Roentgenol. 2008; 191:1339-1346.
10. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenato dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).
Martincich, L. et al. Radiology. 2011; 258(2):396-408.
11. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine.
Knopp, M.V. et al. J. Magn. Reson. Imaging. 2003; 17(6):694-702.
12. Multicenter, Double-Blind, Randomized, Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for MR Angiography of Peripheral Arteries.
Gerretsen, S.C. et al. Radiology. 2010; 255(3):988-1000.
13. Hepatobiliary MR Imaging with Gadolinium-Based Contrast Agents.
Frydrychowicz, A. et al. JMRI J. Magn. Reson. Imaging. 2012 Mar; 35(3):492-511.
14. Magnetic Resonance Imaging of Focal Liver Lesions: Approach to Imaging Diagnosis, Hepatology.
Fowler, K.J. et al. 2011 Dec; 54(6):2227-2237.
15. The Role of Hepatocyte-Specific Contrast Agents in Hepatobiliary Magnetic Resonance Imaging. Se min. Ultrasound CT, and MRI.
Burke , C. et al. 2013 Feb; 34(1):44-53.
16. Low-Dose Gadobenate Dimeglumine versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver: An Intra-Individual Crossover Comparison.
Schneider, G. et al. Investigative Radiology. 2003 Fe b; 38(2):85-94.
17. Accurate Differentiation of Focal Nodular Hyperplasia from Hepatic Adenoma at Gadobenate Dimeglumine-enhanced MR Imaging: Prospective Study.
Grazioli, L. et al. Radiology. 2005 Jul ; 236(1):166-177.
18. Solid Focal Liver Lesions: Dynamic and Late Enhancement Patterns with the Dual Phase Contrast Agent Gadobenate Dimeglumine.
Grazioli, L. et al. J. Gastrointest. Cancer. 2010 Dec; 41(4):221-232.
19. Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration.
Morana, G. et al. Invest. Radiol. 2011 Apr; 46(4):225-239.
20. Liver Vessel Enhancement by Gd-BOPTA and Gd-EOB-DTPA: A Comparison in Healthy Volunteers.
Brismar, T.B. et al. Acta Radiol.2009 Sep;50(7):709-715.
21. Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs. Gadobenate Dimeglumine.
Tirke s, T. et al. J. Comput. Assist. Tomogr. 2015 Jul-Aug; 39(4):479-482.
22. Hepatocellular MR Contrast Agents: Enhancement Characteristics of Liver Parenchyma and Portal Vein after Administration of Gadoxetic Acid in Comparison to Gadobenate Dimeglumine,
Feuerlein, S. et al. Eur. J. of Radiol. 2012 Se p; 81(9):2037-2041.
23. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
Bleicher, A.G.; Kanal, E. AJR Am. J. Roentgenol. 2008; 191(6):W307-11.
24. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.
Kirchi n, M.A. et al. J. Magn. Reson. Imaging. 2001; 14(3):281-94.
25. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock, F.G. et al. Invest. Radiol. 2006; 41(6):500-9.
26. MultiHance®. Resumo das Características do Produto – Bula do Produto.
27. Bracco, dados arquivados.
28. American College of Radiology. Manual on Contrast Media. Version 8, 2012.
Disponíve lem: www.acr.org.
Acessoem: setembro/2020.
Contate-Nos
Por favor, preencha o formulário abaixo e retornaremos para você.